Treatment―guideline, outcome, prognosis:essential thrombocythemia Satoshi Tamaru 1,2 , Masakatsu Nishikawa 2 1Clinical Research Support Center, Mie University Hospital 2Institute of Human Research Promotion and Drug Development, Mie University Graduate School of Medicine Keyword: 本態性血小板血症(ET) , ヒドロキシウレア , アスピリン , インターフェロン pp.287-292
Published Date 2010/3/15
DOI https://doi.org/10.11477/mf.1542102255
  • Abstract
  • Look Inside
  • Reference

Essential thrombocythemia is a myeloproliferative neoplasm that usually has a good prognosis. However, critical management is essential to prevent complications such as thrombosis and hemorrhage. Prudent treatment is required in patients with risk factors, such as age over 60 years, history of thrombosis and hemorrhage, and platelet level over 150×104/μl. Treatment include observation, antiplatelet therapy(acetylsalicylic acid), thrombocytopenic therapy(hydroxyurea, etc.), and plateletpheresis. In pregnant women or those planning to become pregnant, treatment with acetylsalicylic acid, low molecular weight heparin, or interferon is initiated from the early stages of pregnancy in consultation with the OB/GYN to reduce maternal complications such as miscarriage, stillbirth and abruption.

Copyright © 2010, Igaku-Shoin Ltd. All rights reserved.


電子版ISSN 1882-1367 印刷版ISSN 0485-1420 医学書院